Takeda Pharmaceuticals International GmbH

Industry / private company


Location: Zürich, Switzerland (CH) CH

ROR: https://ror.org/002ysmy84

close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Preferences, attitudes and views regarding genetic newborn screening (gNBS) for rare diseases: a systematic review of the literature and synthesis from 2009 to 2022 (2026) Martin S, Kyosovska-Peshtenska G, Audi J, Zarakowska K, Grauman Å, Veldwijk J, Hauber B, et al. Journal article, Review article Efficacy and health-related quality of life associated with second-line vedolizumab after first-line treatment with one anti-TNF in patients with ulcerative colitis: a meta-analysis of the GEMINI-1 and VISIBLE-1 trials (2026) Atreya R, Kirchgesner J, Cheah Z, Biedermann P, Bakker L, Meyer M, Raine T Journal article A decade of clinical data with vedolizumab: the past, present, and future (2026) Jairath V, Armuzzi A, Agboton C, Bressler B, Danese S, Dulai PS, Meyer M, et al. Journal article, Review article Patient preferences in genetic newborn screening for rare diseases: study protocol (2024) Martin S, Angolini E, Audi J, Bertini E, Bruno LP, Coulter J, Ferlini A, et al. Journal article Genetic newborn screening and digital technologies: A project protocol based on a dual approach to shorten the rare diseases diagnostic path in Europe (2023) Garnier N, Berghout J, Zygmunt A, Singh D, Huang KA, Kantz W, Blankart CR, et al. Journal article